Introduction {#jcmm12812-sec-0001}
============

Vitiligo is an acquired depigmenting disorder of great cosmetic importance characterized by loss of melanocytes in the localized epidermis. It affects approximately 0.5--1% of the world population without any racial, sexual predilection in prevalence [1](#jcmm12812-bib-0001){ref-type="ref"}. Despite continuous progress toward an elucidation of the biochemical, genetic and immunopathological pathways in vitiligo over the past decades, the precise pathogenesis remains elusive [2](#jcmm12812-bib-0002){ref-type="ref"}. Recently, epidermal oxidative stress has been documented in vitiligo patients [3](#jcmm12812-bib-0003){ref-type="ref"}. There were several lines of evidence showing impairment in the antioxidant system and reactive oxygen species (ROS)‐mediated damage in melanocytes as well as in the whole body of vitiligo patients, supporting a free‐radical‐mediated damage as an important pathogenic event in melanocyte degeneration [4](#jcmm12812-bib-0004){ref-type="ref"}, [5](#jcmm12812-bib-0005){ref-type="ref"}, [6](#jcmm12812-bib-0006){ref-type="ref"}, [7](#jcmm12812-bib-0007){ref-type="ref"}, [8](#jcmm12812-bib-0008){ref-type="ref"}, [9](#jcmm12812-bib-0009){ref-type="ref"}. Thus, inhibition of oxidative damage may represent prime targets for development of novel therapeutic agents for vitiligo.

Aspirin (acetylsalicylic acid, ASA) is the most common type of nonsteroidal anti‐inflammatory drugs (NSAIDs) and is widely used to treat inflammation and pain. Although many of the pharmacological properties of ASA and other NSAIDs are related to their inhibition of prostaglandin biosynthesis, some of their beneficial therapeutic effects are not completely understood. Recent studies have indicated that ASA has free radical scavenging property and is capable of directly protecting different cells from the deleterious effects of oxidative stress [10](#jcmm12812-bib-0010){ref-type="ref"}, [11](#jcmm12812-bib-0011){ref-type="ref"}, [12](#jcmm12812-bib-0012){ref-type="ref"}, [13](#jcmm12812-bib-0013){ref-type="ref"}. The animal and clinical research also showed that ASA has great preventive and therapeutical effect in many oxidative stress‐relevant diseases [12](#jcmm12812-bib-0012){ref-type="ref"}, [13](#jcmm12812-bib-0013){ref-type="ref"}, [14](#jcmm12812-bib-0014){ref-type="ref"}, [15](#jcmm12812-bib-0015){ref-type="ref"}, [16](#jcmm12812-bib-0016){ref-type="ref"}, [17](#jcmm12812-bib-0017){ref-type="ref"}, [18](#jcmm12812-bib-0018){ref-type="ref"}. Zailaie first showed that low‐dose ASA could protect melanocytes from vitiligo patients against oxidative stress and increase their proliferative capacities [19](#jcmm12812-bib-0019){ref-type="ref"}. Furthermore, a preliminary clinical study has found that the disease activity was suspended in all ASA‐treated vitiligo patients [20](#jcmm12812-bib-0020){ref-type="ref"}. Although Zailaie\'s studies are inspiring, the research has not been replicated to determine whether ASA can protect melanocytes against oxidative stress.

Although extensive studies have been carried out, the mechanism underlining ASA\'s antioxidative action remains unclear. Reports have claimed ASA could increase the expression of antioxidative protein haem oxygenase‐1 (HO‐1), and enhance the nitric oxide production [21](#jcmm12812-bib-0021){ref-type="ref"}, [22](#jcmm12812-bib-0022){ref-type="ref"}. Nitric oxide are well‐known stimulant of nuclear factor E2‐related factor 2 (Nrf2)‐antioxidant response element (ARE) pathway [23](#jcmm12812-bib-0023){ref-type="ref"}. Haem oxygenase‐1 is the downstream molecule of Nrf2‐ARE pathway, and degrades haem to CO, iron and biliverdin [21](#jcmm12812-bib-0021){ref-type="ref"}, [23](#jcmm12812-bib-0023){ref-type="ref"}, [24](#jcmm12812-bib-0024){ref-type="ref"}. Therefore, the antioxidative action of ASA is probably by activating of Nrf2‐ARE pathway.

Nrf2‐ARE pathway is a central part of molecular mechanisms governing the protective function of phase II detoxification and antioxidant enzymes against oxidative stress [25](#jcmm12812-bib-0025){ref-type="ref"}. Under normal circumstances, NRF2 is sequestered in the cytoplasm by a cytosolic repressor Kelch‐like ECH‐associated protein 1 (Keap1). When inducers disrupt its complex with Keap1, NRF2 translocates to the nucleus, binds to ARE and initiates the transcription of genes coding for detoxifying enzymes and cytoprotective proteins. Therefore, any compound which possesses the capacity to alter the interaction of Nrf2--Keap1 could cause the translocation of NRF2 into nuclear to exert some cytoprotective function. Our previously studies have confirmed that Nrf2‐ARE pathway plays an important role in human melanocytes against hydrogen peroxide (H~2~O~2~)‐induced oxidative injury, and its main effecter is HO‐1 [26](#jcmm12812-bib-0026){ref-type="ref"}. Further research demonstrated that the activation of Nrf2‐ARE pathway was defective in melanocytes from vitiligo patients, endowing the melanocytes more vulnerable to oxidative stress [27](#jcmm12812-bib-0027){ref-type="ref"}. Thus, regulation of Nrf2‐ARE pathway may be a promising target for vitiligo treatment.

Given the above, the purpose of this study was to investigate whether ASA exerts a protective effect on human melanocytes against H~2~O~2~‐induced oxidative damage and the underlying molecular mechanism involved. Here, we show that ASA protected human melanocytes against H~2~O~2~‐induced oxidative stress through activation of Nrf2‐ARE pathway and induction of HO‐1 expression. These findings corroborate with previous studies that implicate ASA research as a novel therapeutic strategy against vitiligo.

Materials and methods {#jcmm12812-sec-0002}
=====================

Please see details of the following in the Supplementary Materials online.

ChemicalsAnnexin V‐FITC/PI apoptosis assayMeasurement of intracellular ROS productionLactate dehydrogenase (LDH) release assayTransient transfection and dual luciferase reporter assayLaser scanning confocal immunofluorescence microscopyWestern blot analysis of Nrf2 and p‐Nrf2Transfection of short interfering RNAs (siRNAs)Real‐time PCR analysis

Cell culture {#jcmm12812-sec-0003}
------------

Normal human primary melanocytes were isolated from human forekin specimens obtained during circumcision surgery and identified by S100 and Melan A staining. Approval was obtained from the local ethics committee of Xijing Hospital, and the study was performed in strict compliance with the principles of the Declaration of Helsinki. A written consent was taken from all donors. The melanocytes were maintained in Medium 254 (Cascade Biologics/Invitrogen, Portland, OR, USA) supplemented with Human Melanocyte Growth Supplement (Cascade Biologics/Invitrogen), 5% foetal bovine serum (Invitrogen, San Diego, CA, USA), 100 U/ml penicillin and 100 U/ml streptomycin in a humid atmosphere of 5% CO~2~ at 37°C. The human epidermal melanocyte cell line PIG1 (kindly sent by Dr Caroline Le Poole, Loyola University Chicago, Maywood, IL, USA) were immortalized by retroviral introduction of the human papillomavirus type 16 E6 and E7 genes [28](#jcmm12812-bib-0028){ref-type="ref"} and cultured in the same condition with primary melanocytes as mentioned above (Tables [1](#jcmm12812-tbl-0001){ref-type="table-wrap"} and [2](#jcmm12812-tbl-0002){ref-type="table-wrap"}).

###### 

Primer sequences of Nrf2 siRNA

  Name                                 Primer sequences (5′--3′ orientation)
  ------------------------------------ ---------------------------------------
  NFE2L2‐homo‐1498                     Sense: GCCCAUUGAUGUUUCUGAUTT
  Antisense: AUCAGAAACAUCAAUGGGCTT     
  NFE2L2‐homo‐934                      Sense: CCCGUUUGUAGAUGACAAUTT
  Antisense: AUUGUCAUCUACAAACGGGTT     
  NFE2L2‐homo‐2226                     Sense: GCACCUUAUAUCUCGAAGUTT
  Antisense: ACUUCGAGAUAUAAGGUGCTT     
  NC‐siRNA                             Sense: UUCUCCGAACGUGUCACGUdTdT
  Antisense: ACGUGACACGUUCGGAGAAdTdT   

John Wiley & Sons, Ltd

###### 

Primer sequences for real‐time PCR and accession numbers

  Gene name                      Primer sequences (5′--3′ orientation)   Accession number
  ------------------------------ --------------------------------------- ------------------------
  *Nrf2*                         F: CTTGGCCTCAGTGATTCTGAAGTG             [NM_006164](NM_006164)
  R: CCTGAGATGGTGACAAGGGTTGTA                                            
  *HO‐1*                         F: CAGGAGCTGCTGACCCATGA                 [NM_002133](NM_002133)
  R: AGCAACTGTCGCCACCAGAA                                                
  *NQO‐1*                        F: GGATTGGACCGAGCTGGAA                  [NM_000903](NM_000903)
  R: AATTGCAGTGAAGATGAAGGCAAC                                            
  *GCLC*                         F: GAAGTGGATGTGGACACCAGATG              [NM_001498](NM_001498)
  R: TTGTAGTCAGGATGGTTTGCGATAA                                           
  *GCLM*                         F: GGAGTTCCCAAATCAACCCAGA               [NM_002061](NM_002061)
  R: TGCATGAGATACAGTGCATTCCAA                                            
  *GAPDH*                        F: ATGACATCAAGAAGGTGGTG                 [NM_008084](NM_008084)
  R: CATACCAGGAATGAGCTTG                                                 

F: forward; R: reverse.

John Wiley & Sons, Ltd

Determination of cell viability by CCK‐8 assay {#jcmm12812-sec-0004}
----------------------------------------------

Cell viability was measured using Cell Counting Kit‐8 (CCK‐8; Beyotime Institued of Biotechnology, Haimen, China) to count living cells as described previously [29](#jcmm12812-bib-0029){ref-type="ref"}. Cell Counting Kit‐8 allows convenient assays by utilizing WST‐8, which is bioreduced by cellular dehydrogenases to an orange formazan product that is soluble in tissue culture medium. The amount of formazan produced is directly proportional to the number of living cells. Briefly, primary melanocytes or PIG1 cells were seeded into 96‐well plates at an initial density of 2 × 10^4^ cells/well with a group of blank control wells (without cells) and a group of untreated control wells (cells only treatment with medium). Each incubation was performed in six separate cell culture wells. After incubation with the indicated drugs, 10 μl of kit reagent was added into 100 μl cell solution and incubated for a further 90 min. at 37°C. Cell viability was obtained by monitoring the colour change on an ELISA plate reader (Bio‐Rad, Hercules, CA, USA) setting at an absorbance reading of 450 nm.

Statistical analysis {#jcmm12812-sec-0005}
--------------------

Data are presented as mean ± S.D. A one‐way [anova]{.smallcaps} was used for multiple group comparisons. These analyses were performed by GraphPad Prism (GraphPad Software 3.0; San Diego, CA, USA). Differences between groups were considered to be significant at *P* \< 0.05. Each experiment was performed in triplicate and repeated at least three times.

Results {#jcmm12812-sec-0006}
=======

Aspirin attenuated H~2~O~2~‐induced cytotoxicity in human melanocytes {#jcmm12812-sec-0007}
---------------------------------------------------------------------

In this study, we first evaluated the effect of ASA on cell proliferation, cell viability, melanin content and tyrosinase activity of primary human melanocytes. As it can be observed in Figure [1](#jcmm12812-fig-0001){ref-type="fig"}A, melanocytes pre‐treated with ASA (10--270 μM) induced cell proliferation in a time‐dependent manner, whereas melanocytes pre‐treated with 810 μM ASA significantly inhibited cell growth compare to untreated group. However, ASA (10--810 μM) did not affect melanin content and tyrosinase activity (Fig. S1). The morphologic changes of melanocytes showed that treatment of ASA alone for 24 hrs had no significant effect on cell morphology at the concentrations ranging from 10 to 90 μM. However, 810 μM ASA resulted in cytotoxicity, including cellular dendrites shortening and partial cell death (data not shown). Although the result obtained from CCK‐8 assay demonstrated that 10--270 μM ASA alone had no significant effect on cell viability (Fig. [1](#jcmm12812-fig-0001){ref-type="fig"}C), given the results of proliferation curves and morphologic changes in melanocytes, we decided to use 10--90 μM ASA for the subsequent experiments.

![Protective effect of aspirin on H~2~O~2~‐induced cytotoxicity in primary human melanocytes. (**A**) Primary human melanocytes were treated with different concentrations of aspirin for 1--5 days, and cell proliferation was determined by CCK‐8 assay. (**B**) The effect of aspirin on H~2~O~2~‐induced morphological changes in primary human melanocytes. (**C**) Primary human melanocytes were treated with various concentrations of aspirin alone for 24 hrs, and cell viability was determined by CCK‐8 assay. (**D**) Primary human melanocytes were exposed to various concentrations of aspirin (10, 30 and 90 μM) for 24 hrs. After pre‐treatment, cells were treated with 1.0 mM H~2~O~2~ for 24 hrs, and the cell viability was determined by CCK‐8 assay. Data are presented as the mean ± S.D. of the percentages observed in treated *versus* untreated control cells from three independent experiments. \**P* \< 0.01 *versus* untreated control cells, \*\**P* \< 0.01 *versus* H~2~O~2~‐treated cells, ^\#^ *P* \< 0.01 *versus* H~2~O~2~‐treated cells and ^\#\#^ *P* \< 0.001 *versus* untreated control cells.](JCMM-20-1307-g001){#jcmm12812-fig-0001}

Our previous work has demonstrate that treatment of melanocytes with 1.0 mM H~2~O~2~ for 24 hrs is the most appropriate way to induce consistent and high degree of oxidative damage [4](#jcmm12812-bib-0004){ref-type="ref"}, [26](#jcmm12812-bib-0026){ref-type="ref"}. Here, we investigate whether ASA protects melanocytes from H~2~O~2~‐induced cell death. Primary human melanocytes were treated with 1.0 mM H~2~O~2~ in the presence or absence of ASA (10, 30 and 90 μM), and the cell viability was assessed by cell morphology and CCK‐8 assays. After treatment of 1.0 mM H~2~O~2~ for 24 hrs, the dendrites of melanocytes shortened or disappeared (Fig. [1](#jcmm12812-fig-0001){ref-type="fig"}B, panels b) and cell viability was decreased to about 41% of the control cells (Fig. [1](#jcmm12812-fig-0001){ref-type="fig"}D). However, pre‐treatment with 10--90 μM ASA significantly attenuated H~2~O~2~‐induced oxidative damage in a dose‐dependent manner, as represented by a decreased number of injured cellular dendrites (Fig. [1](#jcmm12812-fig-0001){ref-type="fig"}B, panels e--f) and an increased cell viability of 62% great than the control cells (Fig. [1](#jcmm12812-fig-0001){ref-type="fig"}D).

Aspirin reduced H~2~O~2~‐induced leakage of LDH and the level of intracellular ROS in human melanocytes {#jcmm12812-sec-0008}
-------------------------------------------------------------------------------------------------------

To further prove the protective action of ASA against oxidative damage, we determined LDH release rates and the level of intracellular ROS after treatment with 1.0 mM H~2~O~2~ for 24 hrs in primary human melanocytes. After exposure to H~2~O~2~, LDH release was significantly higher in the H~2~O~2~‐treated cells than in the control cells, indicating that H~2~O~2~ was toxic to primary human melanocytes. In accordance with CCK‐8 assay, H~2~O~2~ treatment markedly increased the LDH release rate of melanocytes and in contrast, the LDH release rate was decreased by pre‐treatment with ASA in a dose‐dependent manner (Fig. [2](#jcmm12812-fig-0002){ref-type="fig"}A).

![Effects of aspirin on LDH release and intracellular ROS levels in primary human melanocytes following H~2~O~2~ challenge. (**A**) LDH leakage of human melanocytes was determined by an LDH release assay. (**B**) Representative results for ROS production after pre‐treatment. (**C**) The fluorescence intensity of the cells was calculated relative to that of untreated control cells. The results shown in A and C are presented as the mean ± S.D. of three independent experiments. \*\**P* \< 0.01 *versus* H~2~O~2~‐treated cells, ^\#^ *P* \< 0.05 and ^\#\#^ *P* \< 0.01 *versus* untreated control cells.](JCMM-20-1307-g002){#jcmm12812-fig-0002}

To determine whether ASA modulates the level of ROS generated in human melanocytes in response to H~2~O~2~ treatment, we measured the intracellular level of ROS by using fluorescent probe DCFH‐DA. As shown in Figure [2](#jcmm12812-fig-0002){ref-type="fig"}B and C, treatment with H~2~O~2~ induced a robust increase in DCF fluorescence level (1.33‐fold compared to the control group). Pre‐treatment with 10--90 μM ASA for 24 hrs significantly reduced the H~2~O~2~‐induced ROS accumulation in primary human melanocytes.

Aspirin protects human melanocytes from H~2~O~2~‐induced apoptosis {#jcmm12812-sec-0009}
------------------------------------------------------------------

To investigate whether ASA protects against H~2~O~2~‐induced apoptosis, primary human melanocytes were pre‐treated with different concentrations of ASA (10, 30 and 90 μM) for 24 hrs before 1.0 mM H~2~O~2~ induction. To quantify the rate of cell apoptosis, flow cytometry analysis was performed with both Annexin‐V‐FITC and PI staining, the average percentages of apoptotic cells were determined as the percentage of Annexin‐V‐FITC stained cells in both Annexin‐V‐FITC and PI treated cells, the results are represented in Figure [3](#jcmm12812-fig-0003){ref-type="fig"}. Typical examples are shown in Figure [3](#jcmm12812-fig-0003){ref-type="fig"}A. After H~2~O~2~ treatment, the percentage of apoptotic cells increased to 20% from a baseline of 5.2% in the control group, whereas pre‐treatment of 10--90 μM ASA markedly inhibited H~2~O~2~‐induced apoptotic death and reduced the percentages of Annexin‐V‐stained cells up to 7.8%.

![Inhibitory effect of aspirin on H~2~O~2~‐induced apoptosis in primary human melanocytes. Cells were pre‐treated with or without aspirin at the indicated concentrations for 24 hrs and then incubated in the presence or absence of 1.0 mM H~2~O~2~ for a further 24 hrs. Cellular apoptosis was assayed by annexin V‐FITC and PI counterstaining and analyzed with flow cytometry. (**A**) The original representative flow cytometry figures. (**B**) The apoptosis rates of human melanocytes. The data are presented as the mean ± S.D. of three independent experiments. \*\**P* \< 0.01 *versus* H~2~O~2~‐treated cells and ^\#\#^ *P* \< 0.01 *versus* untreated control cells.](JCMM-20-1307-g003){#jcmm12812-fig-0003}

Aspirin dramatically induces Nrf2‐mediated transcriptional activation of ARE and HO‐1, and increased NRF2 nuclear translocation, NRF2 and p‐NRF2 expression in human melanocytes {#jcmm12812-sec-0010}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To rule out the roles of Nrf2‐driven transcriptional activation, the mRNA expression profiles of genes regulated by Nrf2 were examined by Real‐time PCR amplification from cells treated with or without ASA. In Figure [4](#jcmm12812-fig-0004){ref-type="fig"}A, treatment with ASA induced an early transcriptional activation of various Nrf2‐driven mRNAs, including HO‐1, NQO1, GCLC and GCLM. Interestingly, pre‐treatment with ASA predominantly induced much earlier and augmented expression of HO‐1 mRNA only among other Nrf2‐driven transcripts. However, transcriptional activation of other Nrf2‐driven transcripts, including as NQO1, GCLC and GCLM were not changed. To further determine whether up‐regulation of HO‐1 by aspirin treatment is caused by Nrf2 pathway, we transfected PIG1 cells with Nrf2 siRNA for 24 hrs, followed by treatment with 90 μM ASA for additional 24 hrs. As shown in Figure [4](#jcmm12812-fig-0004){ref-type="fig"}A, transfection with Nrf2 siRNA significantly reduced ASA‐mediated HO‐1 mRNA expressions compared to control.

![Investigation of Nrf2‐mediated phase II gene modulation, antioxidant response element (ARE) activity, Nrf2 nuclear translocation, NRF2 and p‐NRF2 protein levels in human melanocytes after treatment with aspirin. (**A**) Modulation of HO‐1, NQO‐1, GCLC and GCLM gene expression levels was detected by real‐time PCR in human melanocytes after a 24‐hr aspirin treatment with or without Nrf2‐siRNA or NC‐siRNA treatment. Data are shown as ratios of gene expression in treated cells to that in untreated controls after normalization on the basis of the expression of the GAPDH housekeeping gene. \*\**P* \< 0.01 compared with the untreated cells. ^\#\#^ *P* \< 0.01 compared with the control cells. (**B**) PIG1 cells were cotransfected with an ARE‐luciferase reporter plasmid (pGL3‐ARE) and a Renilla luciferase reporter plasmid (pRLtk) for 24 hrs and treated with aspirin (10, 30 and 90 μM) for 24 hrs before luciferase activity was measured. Firefly luciferase activity in relative light units per second (RLU/s) was normalized to Renilla luciferase activity and expressed as x‐fold multiples of the control to obtain a ratio of the experimental condition to the control (control cells without ASA treatment). \**P* \< 0.05 compared with the control cells. (**C**) NRF2 localization in melanocytes was observed by laser confocal scanning microscopy after treatment with or without aspirin for 24 hrs. Nuclear NRF2 translocation and accumulation occurred in aspirin treatment group (Arrows indicated), scale bar = 50 μm. (**D**) NRF2 and p‐NRF2 protein levels were measured by western blots after treatment with 90 μM aspirin for 24 hrs. (**E**) the intensity of each band was quantified by densitometry analysis. All protein expression was normalized to that of β‐actin, which was used as an internal control. The data are presented as the mean ± S.D. of three independent experiments. \**P* \< 0.05 compared with p‐NRF2 in control group (untreated). ^\#^ *P* \< 0.05 compared with NRF2 in control group (untreated). ^▵^ *P* \< 0.05 compared with p‐NRF2 in only ASA‐treated group. ^▽^ *P* \< 0.05 compared with NRF2 in only ASA‐treated group. Cropped gel images are used in this figure and the gels were run under the same experimental conditions. ^▲^ *P* \> 0.05 compared with p‐NRF2 in control group (untreated). ^▼^ *P* \> 0.05 compared with NRF2 in control group (untreated). ^●^ *P* \> 0.05 compared with p‐NRF2 in only ASA‐treated group. ^■^ *P* \> 0.05 compared with NRF2 in only ASA‐treated group.](JCMM-20-1307-g004){#jcmm12812-fig-0004}

To test our hypothesis that ASA may down‐regulate intracellular ROS and protect melanocytes from H~2~O~2~‐induced oxidative injury by activating Nrf2‐ARE pathway, we investigated the effects of ASA on ARE transcriptional activity, NRF2 nuclear translocation, p‐ NRF2 and NRF2 accumulation. As shown in Figure [4](#jcmm12812-fig-0004){ref-type="fig"}B, ASA significantly increased ARE‐luciferase activity in a dose‐dependent manner. Immunofluorescent analysis revealed that treatment of cells with 90 μM ASA for 24 hrs induced NRF2 nuclear translocation and accumulation (Fig. [4](#jcmm12812-fig-0004){ref-type="fig"}C). To further confirm whether ASA could activate NRF2 in human melanocytes, PIG1 cells were transfected with Nrf2 siRNA for 48 hrs, followed by treatment with 90 μM ASA for additional 24 hrs, and the levels of NRF2 and p‐NRF2 proteins were determined by Western blot analysis. We found that ASA treatment significantly increased the protein levels of both p‐NRF2 and NRF2, whereas transfection with Nrf2 siRNA reduced ASA‐mediated up‐regulation of p‐NRF2 and NRF2 protein expressions (Fig. [4](#jcmm12812-fig-0004){ref-type="fig"}D and E). However, cells treated with NC‐siRNA had no effect (Fig. [4](#jcmm12812-fig-0004){ref-type="fig"}D and E). These results demonstrated that ASA could induce HO‐1 expression by activating Nrf2‐ARE pathway.

Knockdown of Nrf2 expression abrogated the protection action of Aspirin on PIG1 cells against H~2~O~2~‐induced cytotoxicity and oxidative stress {#jcmm12812-sec-0011}
------------------------------------------------------------------------------------------------------------------------------------------------

Next, we investigated whether Nrf2‐driven transcriptional activation was directly involved in eliciting the protective effect of ASA against H~2~O~2~. PIG1 cells were transfected with specific Nrf2 ‐siRNA for 48 hrs and followed by addition of 1.0 mM H~2~O~2~ in the presence of 90 μM ASA for 24 hrs. Figure [5](#jcmm12812-fig-0005){ref-type="fig"}A and C showed that the cytoprotective effect of ASA was significantly suppressed after knockdown of Nrf2 expression, whereas transfection with NC‐siRNA had no effect. In parallel with this observation, pre‐treatment with ASA significantly decreased the H~2~O~2~‐induced apoptotic cells, which was markedly suppressed by down‐regulating the expression of Nrf2 (Fig. [5](#jcmm12812-fig-0005){ref-type="fig"}B and D). Moreover, consistent with previous results, the reduction in intracellular ROS levels by ASA in H~2~O~2~‐treated cells completely disappeared following transfection of Nrf2 siRNA (Fig. [5](#jcmm12812-fig-0005){ref-type="fig"}E and F). However, cells treated with NC‐siRNA samples did not show any change on ASA‐induced apoptosis rate and ROS level under H~2~O~2~‐treatment (Fig. [5](#jcmm12812-fig-0005){ref-type="fig"}B, D--F).

![Effect of Nrf2 siRNA and aspirin on cell viability, apoptosis and intracellular ROS level induced by H~2~O~2~ in PIG1 cells. (**A**) Viability of PIG1 cells pre‐treated with Nrf2 siRNA,NC‐siRNA and/or aspirin (ASA; 90 μM) was determined with CCK‐8 assay 24 hrs after exposure to 1.0 mM H~2~O~2~ (*n* = 3). (**B**) The apoptosis rates of PIG1 cells. (**C**) The effect of Nrf2 siRNA,NC‐siRNA and aspirin on H~2~O~2~‐induced morphological changes in PIG1 cells. (**D**) The original representative flow cytometry figures. (**E**) Representative results for ROS production after pre‐treatment. (**F**) The fluorescence intensity of the cells was calculated relative to that of untreated control cells. The data are presented as the mean ± S.D. of three independent experiments. \*\**P* \< 0.01 and ^\$^ *P* \> 0.05 *versus* H~2~O~2~‐treated cells; ^\#\#^ *P* \< 0.01 *versus* untreated control cells. ^▲^ *P* \> 0.05 *versus* H~2~O~2~+ ASA treated cells.](JCMM-20-1307-g005){#jcmm12812-fig-0005}

Nrf2‐mediated HO‐1 activation is required in protective effect of Aspirin against H~2~O~2~‐induced cytotoxicity and oxidative stress {#jcmm12812-sec-0012}
------------------------------------------------------------------------------------------------------------------------------------

To make sure that the increased expressions of HO‐1 was needed in the antioxidative property of ASA in human melanocytes against H~2~O~2~‐derived oxidative injury, we used Znpp (10 μM), the specific inhibitor of HO‐1, to pre‐treat primary human melanocytes for 24 hrs. The cells were then treated with 90 μM ASA for 24 hrs followed by 1.0 mM H~2~O~2~ for another 24 hrs. The data demonstrated that Znpp alleviated cellular protection afforded by ASA against H~2~O~2~‐mediated toxicity (Fig. [6](#jcmm12812-fig-0006){ref-type="fig"}A). We also verified that pre‐treatment with ASA resulted in a marked decrease in apoptotic cells, which was markedly suppressed by addition of Znpp (Fig. [6](#jcmm12812-fig-0006){ref-type="fig"}B and C). In addition, reduction in ROS level by pre‐treatment with ASA was also abrogated by the addition of Znpp (Fig. [6](#jcmm12812-fig-0006){ref-type="fig"}D and E).

![Effect of Znpp and aspirin on cell viability, apoptosis and intracellular ROS level induced by H~2~O~2~ in PIG1 cells. (**A**) Viability of PIG1 cells pre‐treated with Znpp and/or aspirin (ASA; 90 μM) was determined with CCK‐8 assay 24 hrs after exposure to 1.0 mM H~2~O~2~ (*n* = 3). (**B**) The apoptosis rates of PIG1 cells. (**C**) The original representative flow cytometry figures. (**D**) Representative results for ROS production after pre‐treatment. (**E**) The fluorescence intensity of the cells was calculated relative to that of untreated control cells. The data are presented as the mean ± S.D. of three independent experiments. \*\**P* \< 0.01 and ^\$^ *P* \> 0.05 *versus* H~2~O~2~‐treated cells; ^\#\#^ *P* \< 0.01 *versus* untreated control cells.](JCMM-20-1307-g006){#jcmm12812-fig-0006}

Discussion {#jcmm12812-sec-0013}
==========

Accumulating evidence indicates that oxidative stress plays a critical role in the pathogenesis of vitiligo. An extremely high level of H~2~O~2~ in lesional skin has been reported in vitiligo patients and suggested to be responsible for the disappearance of melanocytes [3](#jcmm12812-bib-0003){ref-type="ref"}. Anti‐oxidative stress‐based remedies are promising strategies for vitiligo; however, the drug development is being hampered by limited understanding of the pharmaceutically relevant molecular targets and structures in most oxidative stress‐relevant diseases.

Acetylsalicylic acid, the most widely used NSAID, had been reported to have free radical scavenging property [10](#jcmm12812-bib-0010){ref-type="ref"}, [11](#jcmm12812-bib-0011){ref-type="ref"} and to be a potent antioxidant in many oxidative stress‐relevant diseases [12](#jcmm12812-bib-0012){ref-type="ref"}, [13](#jcmm12812-bib-0013){ref-type="ref"}, [14](#jcmm12812-bib-0014){ref-type="ref"}, [15](#jcmm12812-bib-0015){ref-type="ref"}, [16](#jcmm12812-bib-0016){ref-type="ref"}, [17](#jcmm12812-bib-0017){ref-type="ref"}, [18](#jcmm12812-bib-0018){ref-type="ref"}. Recently, Zailaie reported that ASA was potently beneficial to vitiligo patients through the inhibition of melanocytes lipid peroxidation and subsequently increased cell proliferation [19](#jcmm12812-bib-0019){ref-type="ref"}. In this study, we have further elucidated that pre‐treatment with ASA was followed by increased resistance of primary human melanocytes to oxidant injury. The capacity of ASA to protect melanocytes *in vitro* may translate into and explain the therapeutic action of ASA in vitiligo patients [19](#jcmm12812-bib-0019){ref-type="ref"}, [20](#jcmm12812-bib-0020){ref-type="ref"}. In our study, cell protection occurred at micromolar concentrations of ASA, which are well within the range of bioavailability in human oral therapy and antithrombotic dosing regimens [30](#jcmm12812-bib-0030){ref-type="ref"}, [31](#jcmm12812-bib-0031){ref-type="ref"}.

Activation of the Nrf2‐ARE signaling pathway is known to protect against oxidative stress‐induced cell death [32](#jcmm12812-bib-0032){ref-type="ref"}, [33](#jcmm12812-bib-0033){ref-type="ref"}, [34](#jcmm12812-bib-0034){ref-type="ref"}, [35](#jcmm12812-bib-0035){ref-type="ref"}, [36](#jcmm12812-bib-0036){ref-type="ref"}. Given the association of ASA with Nrf2‐ARE pathway, we explored the ASA dependent role of Nrf2‐ARE antioxidation in this study. The results demonstrated Nrf2/HO‐1 signaling directly involves in the protective effect of ASA against H~2~O~2~ in primary melanocytes. We established that HO‐1 is a key factor in ASA\'s protection of melanocytes against H~2~O~2~‐induced cellular damage of melanocytes. Furthermore, we proved that ASA dependent induction of HO‐1 protected melanocytes against H~2~O~2~‐induced toxicity and that inhibition of HO‐1 expression abrogated these protective effects of ASA as measured by cytotoxicity and apoptosis. Our previously published work has confirmed that Nrf2‐ARE pathway plays an important role in melanocytes against H~2~O~2~‐induced oxidative injury, and its main effecter is HO‐1 [26](#jcmm12812-bib-0026){ref-type="ref"}. Further research demonstrated that the activation of Nrf2‐ARE pathway in melanocytes from vitiligo patients is defective, thus regulation of the Nrf2/HO‐1 pathway can reduced H~2~O~2~‐induced oxidative damage in human melanocytes [27](#jcmm12812-bib-0027){ref-type="ref"}. Combined with our study, we demonstrated that low dose ASA protected melanocytes from oxidative injury by activating Nrf2‐ARE pathway and inducing HO‐1 expression, which may be an approach to suspend the disease.

Although substantial progress has been made in our understanding of intracellular signaling pathways regulating Nrf2 and its target genes, further studies to clarify detailed molecular milieu of Nrf2 signaling may help design a new class of therapeutically effective antioxidants [25](#jcmm12812-bib-0025){ref-type="ref"}. Nitric oxide and its donors are well‐known antioxidant agents and stimulants of Nrf2‐ARE pathway [23](#jcmm12812-bib-0023){ref-type="ref"}, [37](#jcmm12812-bib-0037){ref-type="ref"}, [38](#jcmm12812-bib-0038){ref-type="ref"}. Acetylsalicylic acid has been reported to increase eNOS activity and enhance nitric oxide production [22](#jcmm12812-bib-0022){ref-type="ref"}, [39](#jcmm12812-bib-0039){ref-type="ref"}. These findings point to the involvement of endogenous nitric oxide as signaling molecule in ASA\'s antioxidative action. Whether nitric oxide is involved in the ASA‐dependent Nrf2‐ARE pathway activation need to be further investigated. Recently, a wide variety of dietary and synthetic compounds have been reported to induce Nrf2, and thereby enhancing ARE driven gene transcription to eventually exert anti‐oxidative activities [25](#jcmm12812-bib-0025){ref-type="ref"}. Our study proved ASA facilitated translocation of Nrf2 to the nucleus, where it bound to ARE, and eventually resulting in the transcriptional regulation of HO‐1 gene, which suggested it may be used as a new antioxidant. If confirmed, the cheap and most widely used NSAID, will have potent beneficial to vitiligo and other oxidative‐relevant diseases.

In conclusion, we have demonstrated that ASA protected melanocytes from oxidative injury by activation of Nrf2‐ARE pathway and induction of HO‐1 expression. Thus, ASA might represent a promising new therapeutic agent for vitiligo. More experimental and clinical research is needed to further confirm the exact effect and mechanisms of ASA in the treatment of vitiligo patients.
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